COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults.

COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults.

Publication date: May 22, 2020

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug-drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials.

We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking which would interact with hydroxychloroquine.

We reanalyzed data from the cohort of patients 65?years and older enrolled in the MedSafer pilot study. We first identified patients taking medications with potentially harmful drug-drug interactions with hydroxychloroquine that might exclude them from participation in a typical coronavirus disease 2019 (COVID-19) therapeutic trial. Next, we identified medications that were flagged by MedSafer as being potentially inappropriate and crafted guidance around medication management if contemplating the use of hydroxychloroquine.

The cohort contained a total of 1,001 unique patients with complete data on their home medications at admission. Of these 1,001 patients, 590 (58.9%) were receiving one or more home medications that could potentially interact with hydroxychloroquine, and of these 255 (43.2%) were flagged as potentially inappropriate by the MedSafer tool. Common classes of PIMs observed were antipsychotics, cardiac medications, and anti-diabetic agents.

The COVID-19 pandemic highlights the importance of medication optimization and deprescribing PIMs in older adults. By acting now to reduce polypharmacy and use of PIMs, we can better prepare this vulnerable population for inclusion in trials and, if substantiated, pharmacologic treatment or prevention of COVID-19. This article is protected by copyright. All rights reserved.

Concepts Keywords
Antimalarial Drug Medication management
Antipsychotics Infection
Cohort Polypharmacy
Common Health
Coronavirus Clinical pharmacology
Diabetic Pharmacokinetics
Hydroxychloroquine Geriatrics
Infection Unnecessary health care
Interact Pharmaceuticals policy
Morbidity Deprescribing
Mortality Polypharmacy
Optimization Hydroxychloroquine
Pandemic Drug interaction
Pharmacologic Antimalarial medication
PIMs Coronavirus
SAFER
SARS

Semantics

Type Source Name
drug DRUGBANK Hydroxychloroquine
disease MESH Drug Interactions
disease MESH infection
disease MESH chronic illnesses
drug DRUGBANK Tropicamide

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *